Alvotech announced on 9 February 2023 that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT04, their proposed biosimilar to Stelara (ustekinumab).
EMA accepts application for ustekinumab biosimilar AVT04
Biosimilars/News | Posted 03/03/2023 0 Post your comment
Ustekinumab is indicated for the treatment of Crohn’s disease, psoriasis and psoriatic arthritis, and the originator is Janssen’s Stelara. It is a humanized monoclonal antibody that interferes with the triggering of the body’s inflammatory response through the suppression of certain cytokines. Specifically, it blocks interleukin IL 12 and IL 23 which help activate certain T cells. It binds to the p 40 subunit of both IL 12 and IL 23 so that they subsequently cannot bind to their receptors .
The patents on Stelara are due to expire in the US in September 2023 and in Europe in January 2024 . Alvotech’s AVT04 has already been approved by the Food and Drug Administration in the US . In the US the product is to be launched with marketing partner Teva, whereas in Europe the marketing partnership is with Stada. Alvotech is also partnered with Cipla Gulf to bring the product to market in emerging markets in Arabia and Africa .
Alvotech and Stada hope that EMA will recommend approving a marketing authorization for AVT04 later in 2023.
Clinical trials begin for ustekinumab biosimilars
Alvotech signs agreement for ustekinumab biosimilar Stelara in Japan
LATIN AMERICAN FORUM
View the latest headline article: Directrices revisadas de la OMS para productos biosimilares seguros y eficaces
Browse the news in the Latin American Forum!
Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.
Ver el último artículo de cabecera: Directrices revisadas de la OMS para productos biosimilares seguros y eficaces
!Explore las noticias en el Foro Latinoamericano!
Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.
1. GaBI Online - Generics and Biosimilars Initiative. [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Mar 3]. Available from: www.gabionline.net/biosimilars/general/biosimilars-of-ustekinumab
2. Derbyshire M. Patent expiry dates for biologicals: 2018 update. Generics and Biosimilars Initiative Journal (GaBI Journal). 2019;8(1):24-31. doi: 10.5639/gabij.2019.0801.003
3. GaBI Online - Generics and Biosimilars Initiative. Biosimilar advances for Alvotech-Teva and setback for Biocon Biologics [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Mar 3]. Available from: www.gabionline.net/biosimilars/news/biosimilar-advances-for-alvotech-teva-and-setback-for-biocon-biologics
4. GaBI Online - Generics and Biosimilars Initiative. Alvotech and Cipla Gulf partnership announced [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2023 Mar 3]. Available from:
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2023 Pro Pharma Communications International. All Rights Reserved.
Post your comment
High mannose glycans in biosimilars and their pharmacokinetic impact
Biosimilars in Southern European Hospital Markets: barriers and determinants of uptake
An update on the joint EMA-HMA statement on interchangeability of biosimilar
Biosimilars switching policies for Canada’s Newfoundland and Labrador, and Yukon
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Post your comment